Article
Efficacy of two alternate vaccines based on Plasmodium falciparum merozoite surface protein 1 in an Aotus challenge trial.
Infection and immunity - 1 Mar 2001
Stowers A W, Cioce V, Shimp R L, Lawson M, Hui G, Muratova O, Kaslow D C, Robinson R, Long C A, Miller L H
Abstract excerpt
In an attempt to produce a more defined, clinical-grade version of a vaccine based on Plasmodium falciparum merozoite surface protein 1 (MSP1), we evaluated the efficacy of two recombinant forms of MSP1 in an Aotus nancymai challenge model system. One recombinant vaccine, bvMSP1(42), based on the 42-kDa C-terminal portion of MSP1, was expressed as a secreted protein in baculovirus-infected insect cells. A highly...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.